GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Caliber Imaging & Diagnostics Inc (OTCPK:LCDX) » Definitions » Financial Strength

Caliber Imaging & Diagnostics (Caliber Imaging & Diagnostics) Financial Strength : 0 (As of Mar. 2014)


View and export this data going back to 2012. Start your Free Trial

What is Caliber Imaging & Diagnostics Financial Strength?

Caliber Imaging & Diagnostics has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Caliber Imaging & Diagnostics did not have earnings to cover the interest expense. Caliber Imaging & Diagnostics's debt to revenue ratio for the quarter that ended in Mar. 2014 was 1.49. As of today, Caliber Imaging & Diagnostics's Altman Z-Score is 0.00.


Competitive Comparison of Caliber Imaging & Diagnostics's Financial Strength

For the Medical Devices subindustry, Caliber Imaging & Diagnostics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caliber Imaging & Diagnostics's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Caliber Imaging & Diagnostics's Financial Strength distribution charts can be found below:

* The bar in red indicates where Caliber Imaging & Diagnostics's Financial Strength falls into.



Caliber Imaging & Diagnostics Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Caliber Imaging & Diagnostics's Interest Expense for the months ended in Mar. 2014 was $-0.22 Mil. Its Operating Income for the months ended in Mar. 2014 was $-1.59 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2014 was $0.00 Mil.

Caliber Imaging & Diagnostics's Interest Coverage for the quarter that ended in Mar. 2014 is

Caliber Imaging & Diagnostics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Caliber Imaging & Diagnostics's Debt to Revenue Ratio for the quarter that ended in Mar. 2014 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2014 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.124 + 0) / 3.432
=1.49

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Caliber Imaging & Diagnostics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Caliber Imaging & Diagnostics  (OTCPK:LCDX) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Caliber Imaging & Diagnostics has the Financial Strength Rank of 0.


Caliber Imaging & Diagnostics Financial Strength Related Terms

Thank you for viewing the detailed overview of Caliber Imaging & Diagnostics's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Caliber Imaging & Diagnostics (Caliber Imaging & Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
100 Burtt Road, Suite 203, Andover, MA, USA, 01810
Caliber Imaging & Diagnostics Inc is a medical device company engaged in developing, manufacturing, marketing & selling point-of-care cellular imaging systems to diagnose skin cancer. It offers clinical imaging and research imaging solutions that shows tissue at the cellular level. Its products portfolio includes; VivaScope; VivaScope 3000, 1500 & 2500; and VivaNet and VivaScan.
Executives
Paul Stuka director C/O OSIRIS PARTNERS, LLC, ONE LIBERTY SQUARE, 5TH FLOOR, BOSTON MA 02109
William J Shea director, 10 percent owner 11825 N PENNSYLVANIA ST, CARMEL IN 46032
Kevin M Cronin director
Richard Christopher officer: Chief Financial Officer C/O LUCID, INC., 50 METHODIST HILL DR, SUITE 1000, ROCHESTER NY 14623
Martin Joseph Joyce officer: Chief Financial Officer 1050 HINGHAM STREET, ROCKLAND MA 02370
Matthew S Cox director 58 OAKWOOD DRIVE, CHAPEL HILL NC 27517

Caliber Imaging & Diagnostics (Caliber Imaging & Diagnostics) Headlines